18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis

Peter C. Grayson, Sara Alehashemi, Armin A. Bagheri, Ali Cahid Civelek, Thomas R. Cupps, Mariana J. Kaplan, Ashkan A. Malayeri, Peter A. Merkel, Elaine Novakovich, David A. Bluemke, Mark A. Ahlman

Research output: Contribution to journalArticle

Abstract

Objective: To assess the clinical value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a prospective cohort of patients with large vessel vasculitis (LVV) and comparator subjects. Methods: Patients with Takayasu arteritis and giant cell arteritis were studied, along with a comparator group consisting of patients with hyperlipidemia, patients with diseases that mimic LVV, and healthy controls. Participants underwent clinical evaluation and FDG-PET imaging, and patients with LVV underwent serial imaging at 6-month intervals. We calculated sensitivity and specificity of FDG-PET interpretation for distinguishing patients with clinically active LVV from comparator subjects and from patients with disease in clinical remission. A qualitative summary score based on global arterial FDG uptake, the PET Vascular Activity Score (PETVAS), was used to study associations between activity on PET scan and clinical characteristics and to predict relapse. Results: A total of 170 FDG-PET scans were performed in 115 participants (56 patients with LVV and 59 comparator subjects). FDG-PET distinguished patients with clinically active LVV from comparator subjects with a sensitivity of 85% (95% confidence interval [95% CI] 69, 94) and a specificity of 83% (95% CI 71, 91). FDG-PET scans were interpreted as active vasculitis in most patients with LVV in clinical remission (41 of 71 [58%]). Clinical disease activity status, disease duration, body mass index, and glucocorticoid use were independently associated with activity on PET scan. Among patients who underwent PET during clinical remission, future clinical relapse was more common in patients with a high PETVAS than in those with a low PETVAS (55% versus 11%; P = 0.03) over a median follow-up period of 15 months. Conclusion: FDG-PET provides information about vascular inflammation that is complementary to, and distinct from, clinical assessment in LVV. FDG-PET scan activity during clinical remission was associated with future clinical relapse.

LanguageEnglish (US)
Pages439-449
Number of pages11
JournalArthritis and Rheumatology
Volume70
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Vasculitis
Positron-Emission Tomography
Biomarkers
Blood Vessels
Recurrence
Confidence Intervals
Takayasu Arteritis
Giant Cell Arteritis
Hyperlipidemias
Glucocorticoids
Body Mass Index
Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Grayson, P. C., Alehashemi, S., Bagheri, A. A., Civelek, A. C., Cupps, T. R., Kaplan, M. J., ... Ahlman, M. A. (2018). 18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. Arthritis and Rheumatology, 70(3), 439-449. DOI: 10.1002/art.40379

18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. / Grayson, Peter C.; Alehashemi, Sara; Bagheri, Armin A.; Civelek, Ali Cahid; Cupps, Thomas R.; Kaplan, Mariana J.; Malayeri, Ashkan A.; Merkel, Peter A.; Novakovich, Elaine; Bluemke, David A.; Ahlman, Mark A.

In: Arthritis and Rheumatology, Vol. 70, No. 3, 01.03.2018, p. 439-449.

Research output: Contribution to journalArticle

Grayson, PC, Alehashemi, S, Bagheri, AA, Civelek, AC, Cupps, TR, Kaplan, MJ, Malayeri, AA, Merkel, PA, Novakovich, E, Bluemke, DA & Ahlman, MA 2018, '18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis' Arthritis and Rheumatology, vol. 70, no. 3, pp. 439-449. DOI: 10.1002/art.40379
Grayson, Peter C. ; Alehashemi, Sara ; Bagheri, Armin A. ; Civelek, Ali Cahid ; Cupps, Thomas R. ; Kaplan, Mariana J. ; Malayeri, Ashkan A. ; Merkel, Peter A. ; Novakovich, Elaine ; Bluemke, David A. ; Ahlman, Mark A./ 18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. In: Arthritis and Rheumatology. 2018 ; Vol. 70, No. 3. pp. 439-449
@article{de8e238571b6482b81d67a2eb3a383b8,
title = "18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis",
abstract = "Objective: To assess the clinical value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a prospective cohort of patients with large vessel vasculitis (LVV) and comparator subjects. Methods: Patients with Takayasu arteritis and giant cell arteritis were studied, along with a comparator group consisting of patients with hyperlipidemia, patients with diseases that mimic LVV, and healthy controls. Participants underwent clinical evaluation and FDG-PET imaging, and patients with LVV underwent serial imaging at 6-month intervals. We calculated sensitivity and specificity of FDG-PET interpretation for distinguishing patients with clinically active LVV from comparator subjects and from patients with disease in clinical remission. A qualitative summary score based on global arterial FDG uptake, the PET Vascular Activity Score (PETVAS), was used to study associations between activity on PET scan and clinical characteristics and to predict relapse. Results: A total of 170 FDG-PET scans were performed in 115 participants (56 patients with LVV and 59 comparator subjects). FDG-PET distinguished patients with clinically active LVV from comparator subjects with a sensitivity of 85{\%} (95{\%} confidence interval [95{\%} CI] 69, 94) and a specificity of 83{\%} (95{\%} CI 71, 91). FDG-PET scans were interpreted as active vasculitis in most patients with LVV in clinical remission (41 of 71 [58{\%}]). Clinical disease activity status, disease duration, body mass index, and glucocorticoid use were independently associated with activity on PET scan. Among patients who underwent PET during clinical remission, future clinical relapse was more common in patients with a high PETVAS than in those with a low PETVAS (55{\%} versus 11{\%}; P = 0.03) over a median follow-up period of 15 months. Conclusion: FDG-PET provides information about vascular inflammation that is complementary to, and distinct from, clinical assessment in LVV. FDG-PET scan activity during clinical remission was associated with future clinical relapse.",
author = "Grayson, {Peter C.} and Sara Alehashemi and Bagheri, {Armin A.} and Civelek, {Ali Cahid} and Cupps, {Thomas R.} and Kaplan, {Mariana J.} and Malayeri, {Ashkan A.} and Merkel, {Peter A.} and Elaine Novakovich and Bluemke, {David A.} and Ahlman, {Mark A.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1002/art.40379",
language = "English (US)",
volume = "70",
pages = "439--449",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - 18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis

AU - Grayson,Peter C.

AU - Alehashemi,Sara

AU - Bagheri,Armin A.

AU - Civelek,Ali Cahid

AU - Cupps,Thomas R.

AU - Kaplan,Mariana J.

AU - Malayeri,Ashkan A.

AU - Merkel,Peter A.

AU - Novakovich,Elaine

AU - Bluemke,David A.

AU - Ahlman,Mark A.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: To assess the clinical value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a prospective cohort of patients with large vessel vasculitis (LVV) and comparator subjects. Methods: Patients with Takayasu arteritis and giant cell arteritis were studied, along with a comparator group consisting of patients with hyperlipidemia, patients with diseases that mimic LVV, and healthy controls. Participants underwent clinical evaluation and FDG-PET imaging, and patients with LVV underwent serial imaging at 6-month intervals. We calculated sensitivity and specificity of FDG-PET interpretation for distinguishing patients with clinically active LVV from comparator subjects and from patients with disease in clinical remission. A qualitative summary score based on global arterial FDG uptake, the PET Vascular Activity Score (PETVAS), was used to study associations between activity on PET scan and clinical characteristics and to predict relapse. Results: A total of 170 FDG-PET scans were performed in 115 participants (56 patients with LVV and 59 comparator subjects). FDG-PET distinguished patients with clinically active LVV from comparator subjects with a sensitivity of 85% (95% confidence interval [95% CI] 69, 94) and a specificity of 83% (95% CI 71, 91). FDG-PET scans were interpreted as active vasculitis in most patients with LVV in clinical remission (41 of 71 [58%]). Clinical disease activity status, disease duration, body mass index, and glucocorticoid use were independently associated with activity on PET scan. Among patients who underwent PET during clinical remission, future clinical relapse was more common in patients with a high PETVAS than in those with a low PETVAS (55% versus 11%; P = 0.03) over a median follow-up period of 15 months. Conclusion: FDG-PET provides information about vascular inflammation that is complementary to, and distinct from, clinical assessment in LVV. FDG-PET scan activity during clinical remission was associated with future clinical relapse.

AB - Objective: To assess the clinical value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a prospective cohort of patients with large vessel vasculitis (LVV) and comparator subjects. Methods: Patients with Takayasu arteritis and giant cell arteritis were studied, along with a comparator group consisting of patients with hyperlipidemia, patients with diseases that mimic LVV, and healthy controls. Participants underwent clinical evaluation and FDG-PET imaging, and patients with LVV underwent serial imaging at 6-month intervals. We calculated sensitivity and specificity of FDG-PET interpretation for distinguishing patients with clinically active LVV from comparator subjects and from patients with disease in clinical remission. A qualitative summary score based on global arterial FDG uptake, the PET Vascular Activity Score (PETVAS), was used to study associations between activity on PET scan and clinical characteristics and to predict relapse. Results: A total of 170 FDG-PET scans were performed in 115 participants (56 patients with LVV and 59 comparator subjects). FDG-PET distinguished patients with clinically active LVV from comparator subjects with a sensitivity of 85% (95% confidence interval [95% CI] 69, 94) and a specificity of 83% (95% CI 71, 91). FDG-PET scans were interpreted as active vasculitis in most patients with LVV in clinical remission (41 of 71 [58%]). Clinical disease activity status, disease duration, body mass index, and glucocorticoid use were independently associated with activity on PET scan. Among patients who underwent PET during clinical remission, future clinical relapse was more common in patients with a high PETVAS than in those with a low PETVAS (55% versus 11%; P = 0.03) over a median follow-up period of 15 months. Conclusion: FDG-PET provides information about vascular inflammation that is complementary to, and distinct from, clinical assessment in LVV. FDG-PET scan activity during clinical remission was associated with future clinical relapse.

UR - http://www.scopus.com/inward/record.url?scp=85041590355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041590355&partnerID=8YFLogxK

U2 - 10.1002/art.40379

DO - 10.1002/art.40379

M3 - Article

VL - 70

SP - 439

EP - 449

JO - Arthritis and Rheumatology

T2 - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -